Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests (Tables)

v3.19.3
Non-Controlling Interests (Tables)
9 Months Ended
Sep. 30, 2019
Non-Controlling Interests  
Schedule of non-controlling interests in consolidated entities

Non-controlling interests in consolidated entities are as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of September 30, 2019

 

 

 

 

 

 

Net loss attributable to

 

Non-controlling interests

 

Non-controlling

 

($ in thousands)

    

NCI equity share

 

non-controlling interests

 

in consolidated entities

 

ownership

 

Aevitas

 

$

(1,160)

 

$

(491)

 

$

(1,651)

 

35.8

%

Avenue (2)

 

 

24,114

 

 

(14,869)

 

 

9,245

 

77.3

%

Cellvation

 

 

(726)

 

 

(129)

 

 

(855)

 

21.1

%

Checkpoint (1)

 

 

14,907

 

 

(10,525)

 

 

4,382

 

69.9

%

Coronado SO

 

 

(290)

 

 

 —

 

 

(290)

 

13.0

%

Cyprium

 

 

(306)

 

 

(106)

 

 

(412)

 

10.6

%

Helocyte

 

 

(4,229)

 

 

(181)

 

 

(4,410)

 

19.3

%

JMC

 

 

(216)

 

 

197

 

 

(19)

 

6.9

%

Mustang (2)

 

 

61,899

 

 

(18,053)

 

 

43,846

 

70.2

%

Tamid

 

 

(551)

 

 

(80)

 

 

(631)

 

23.4

%

Total

 

$

93,442

 

$

(44,237)

 

$

49,205

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2018

 

 

 

 

 

 

Net loss attributable to 

 

Non-controlling interests 

 

Non-controlling 

 

($ in thousands)

    

NCI equity share

    

non-controlling interests

    

 in consolidated entities

    

 ownership

 

Aevitas

 

$

(474)

 

$

(606)

 

$

(1,080)

 

36.1

%

Avenue (2)

 

 

13,326

 

 

(13,735)

 

 

(409)

 

64.8

%

Caelum(3)

 

 

(2,436)

 

 

(2,413)

 

 

(4,849)

 

36.8

%

Cellvation

 

 

(457)

 

 

(185)

 

 

(642)

 

21.1

%

Checkpoint (1)

 

 

31,648

 

 

(23,470)

 

 

8,178

 

69.3

%

Coronado SO

 

 

(290)

 

 

 —

 

 

(290)

 

13.0

%

Cyprium

 

 

(210)

 

 

(62)

 

 

(272)

 

10.8

%

Helocyte

 

 

(3,372)

 

 

(684)

 

 

(4,056)

 

19.8

%

JMC

 

 

(475)

 

 

245

 

 

(230)

 

6.9

%

Mustang (2)

 

 

38,631

 

 

(16,628)

 

 

22,003

 

60.5

%

Tamid

 

 

(211)

 

 

(251)

 

 

(462)

 

23.4

%

Total

 

$

75,680

 

$

(57,789)

 

$

17,891

 

  

 

 

Note 1: Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Note 2: Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.

Note 3: Effective January 30, 2019, Caelum ceased to be a controlled Fortress entity and as such is no longer consolidated.